Intrahepatic Cholangiocarcinoma

Showing NaN - NaN of 17

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Intrahepatic Cholangiocarcinoma Trial in Shanghai (HMPL-453, Rabeprazole)

Active, not recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Shanghai Xuhui Central Hospital
Jun 24, 2023

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cadonilimab+Gem/Cis)

Active, not recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Eastern hepatobilliary surgery hospital
Mar 22, 2023

Intrahepatic Cholangiocarcinoma Trial in China, United States (Extend LymphAdenectomy)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Extend LymphAdenectomy
  • Baltimore, Maryland
  • +12 more
Nov 7, 2022

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Toripalimab, Lenvatinib mesylate capsules, Placebo IV)

Not yet recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Zhongshan Hospital affiliated to Fudan University
Aug 12, 2022

Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in China (Observation)

Recruiting
  • Primary Liver Cancer
  • +3 more
  • Observation
  • Beijing, Beijing, China
  • +4 more
Jun 14, 2022

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Camrelizumab, US/CT-guided Percutaneous Cryoablation)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 1, 2022

Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)

Withdrawn
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Zhongshan hospital, Fudan University
Mar 22, 2022

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Sintilimab, Lenvatinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 23, 2021

Intrahepatic Cholangiocarcinoma Trial in Shanghai (cryoablation, Sintilimab, lenvatinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 23, 2021

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Tislelizumab, TACE)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 13, 2021

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Gemox combimed PD1 antibody)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Gemox combimed PD1 antibody
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 7, 2021

Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib Trial in Shanghai (Neoadjuvant treatment)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • Neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 5, 2021

Intrahepatic Cholangiocarcinoma Trial in Shanghai (PD-1 blocking antibody SHR-1210, Capecitabine)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    180 Fenglin Road
Sep 26, 2020

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Bortezomib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, Shanghai, China
    Easter hepatobiliary surgery hospital
Nov 15, 2017

Intrahepatic Cholangiocarcinoma Trial in Shanghai (conventional lymph node dissection, unconventional lymph node dissection)

Unknown status
  • Intrahepatic Cholangiocarcinoma
  • conventional lymph node dissection
  • unconventional lymph node dissection
  • Shanghai, Shanghai, China
    Eastern hepatobilliary surgery hospital
Mar 30, 2016

Intrahepatic Cholangiocarcinoma Trial in Shanghai (TACE+Tegafur, TACE)

Unknown status
  • Intrahepatic Cholangiocarcinoma
  • TACE+Tegafur
  • TACE
  • Shanghai, Shanghai, China
    Eastern hepatobilliary surgery hospital
Mar 30, 2016

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Resection, Radiotherapy)

Unknown status
  • Intrahepatic Cholangiocarcinoma
  • Resection
  • Radiotherapy
  • Shanghai, Shanghai, China
    Eastern Hepatobiliary Surgery Hospital
Mar 30, 2016